Postoperative pain control and quality of life following the use of preemptive celecoxib in mandibular third molar surgery

Stephen Solomon0 sites62 target enrollmentSeptember 24, 2023

Overview

No summary available.

Registry

who.int

Start Date

September 24, 2023

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Stephen Solomon

•1\.Patients within the age ranges of 18 to 50 years.
•2\.Patients who shall be willing to keep instructions and follow\-up appointments.
•3\.Patients with mandibular third molar impaction requiring surgical extraction
•4\.Patients who give their consent to be part of the study
•5\.American Society of Anaesthesiologist physical status classification I (ASA I) patients

•1\.Patients with a history of allergy to celecoxib.
•2\.Patients who are allergic to penicillins and metronidazole
•3\.Patients who used NSAIDs or any other analgesic within 24 hours before the procedure
•4\.Patients with a bleeding disorder or on anticoagulant
•5\.Patients with peptic ulcer disease, kidney disease, asthma or any medical condition that contradict the use of NSAIDs.
•6\.Pregnant women
•7\.Patients with periapical cysts or tumours related to the impacted third molar
•8\.Patients that could not be able to rate their pain intensity on the VAS due to medical conditions such as problems with vision, mental retardation, cognitive disorder, or any other reason.
•9\.Patients who smoke, take alcohol or abuse drugs (illicit drugs)